Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 274

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 274
---
aceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. We conduct our business through our Oncology/Immunology and Other Ventures operations.

Through our Oncology/Immunology operations, our team of approximately 890 scientists and staff has created, developed and in-licensed a deep portfolio of more than 20 drug candidates. We have advanced more than 13 oncology drug candidates to clinical trials in China, with three also in active clinical development in the United States and Europe. We have brought three of our internally developed drugs, savolitinib, fruquintinib and surufatinib (marketed as Orpathys, Elunate and Sulanda, respectively) to patients in China including Macau and Hong Kong. Fruquintinib also received marketing approval in the United States in 2023 and Europe and Japan in 2024 (marketed as Fruzaqla). Moreover, tazemetostat has been approved and launched in Hainan Pilot Zone, Macau and Hong Kong. We also have additional drug candidates in earlier stage clinical development (Phase I/Ib and Phase Ib/II proof-of-concept studies) and several advanced pre-clinical drug candidates. These drug candidates are being developed to treat a wide spectrum of diseases, including solid tumors, hematological malignancies and immunological diseases which we believe may address unmet medical needs and represent large commercial opportunities. Our success in research and development has led to partnerships with leading global pharmaceutical companies, including AstraZeneca, Eli Lilly and Takeda. We and our collaboration partners have invested approximately $2.1 billion in our Oncology/Immunology operations as of December 31, 2024, with almost all of these funds used for research and development expenses for the development of our drug candidates. Net loss attributable to our company from our Oncology/Immunology operations was $385.4 million for the year ended December 31, 2022, net income attributable to our company from our Oncology/Immunology operations was $51.2 million for the year ended December 31, 2023 and net loss attributable to our company from our Oncology/Immunology operations was $24.6 million for the year ended December 31, 2024.

In addition, we have built large-scale and profitable drug marketing and distribution capabilities through subsidiaries and a joint venture in our